2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 813

Prevalence of Gastroesophageal Disease in Systemic Sclerosis and Its Impact on Lung Disease: Fact or Fiction
Abstract Number: 2232

Prevalence of Gout in the Surviving U.S. Solid Organ Transplant Population
Abstract Number: 897

Prevalence of Inflammatory and Chronic Changes Suggestive of Axial Spondyloarthritis in Magnetic Resonance Images of the Axial Skeleton in Individuals < 45 Years in the General Populationas Part of a Large Community Study (SHIP)
Abstract Number: 430

Prevalence of Intra-Articular Mineralization on Knee CT in Persons with or at Risk of Knee Osteoarthritis
Abstract Number: 541

Prevalence of Sjögren’s Syndrome in Patients with RA Enrolled in a Large Observational US Registry
Abstract Number: 1614

Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis
Abstract Number: 1646

Prevalence of Spondyloarthritis in Patients with Anterior Uveitis
Abstract Number: 2131

Prevalence of Systemic Lupus Erythematosus (SLE) and Associated Comorbidities in the 2011-2015 Medicare Population
Abstract Number: 2237

Prevalence of Urate-Lowering Therapy Use and Target Urate Level Achievement Among Gout Patients in the United States (National Health And Nutrition Examination Survey [NHANES] 2007-2014)
Abstract Number: 1129

Prevalence, Incidence, Determinants, and Impacts of Depression and Anxiety in Gout: A Systematic Review
Abstract Number: 874

Preventing a Large Majority of Incident Gout Cases By Modifying Key Risk Factors: Findings from a Prospective Cohort of 44,629 Men over 26 Years
Abstract Number: 2137

Primary Antiphospholipid Syndrome with Vascular Manifestations Is a Rare Disease: A Population-Based, Multi-Source Study Assessing the Prevalence and Incidence in Adults
Abstract Number: 830

Primary Central Nervous System Vasculitis with Tumor-like Presentation
Abstract Number: 1585

Primary Sjögren’s Syndrome Stratification Based on the Severity of Patient-Reported Fatigue
Abstract Number: 1497

PRISM-RA: A Personalized Medicine Test That Accurately Predicts Rheumatoid Arthritis Patients Who Will Not Respond Adequately to Tumor Necrosis Factor Inhibitors

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].